R. Wood

First name
R.
Last name
Wood
Coates, G., Clewes, P., Lohan, C., Stevenson, H., Wood, R., Tritton, T., et al. (2023). Health economic impact of moderate-to-severe chronic pain associated with osteoarthritis in England: a retrospective analysis of linked primary and secondary care data. Bmj Open, 13, e067545. http://doi.org/10.1136/bmjopen-2022-067545
View
Requena, G., Czira, A., Banks, V., Wood, R., Tritton, T., Castillo, C. M., et al. (2023). Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England. Int J Chron Obstruct Pulmon Dis, 18, 1431-1444. http://doi.org/10.2147/copd.s411437
View
Czira, A., Requena, G., Banks, V., Wood, R., Tritton, T., Castillo, C. M., et al. (2023). Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β(2)-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England. Int J Chron Obstruct Pulmon Dis, 18, 643-659. http://doi.org/10.2147/copd.s405498
View
Requena, G., Banks, V., Czira, A., Wood, R., Tritton, T., Wild, R., et al. (2023). Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England. Int J Chron Obstruct Pulmon Dis, 18, 231-245. http://doi.org/10.2147/copd.s389281
View
von Arx, L. B., Rachman, J., Webb, J., Casey, C., Patel, A., Diomatari, C., et al. (2023). Therapeutic inertia related to the injectable glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in patients with type 2 diabetes in UK primary care. Diabetes Obes Metab. http://doi.org/10.1111/dom.14985
View
Halpin, D. M. G., Rothnie, K. J., Banks, V., Czira, A., Compton, C., Wood, R., et al. (2022). Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting. Int J Chron Obstruct Pulmon Dis, 17, 2417-2429. http://doi.org/10.2147/copd.s370540
View
Czira, A., Banks, V., Requena, G., Wood, R., Tritton, T., Wild, R., et al. (2022). Characterisation of patients with chronic obstructive pulmonary disease initiating single-device inhaled corticosteroids/long-acting β(2)-agonist dual therapy in a primary care setting in England. Bmj Open Respir Res, 9. http://doi.org/10.1136/bmjresp-2022-001243
View
Requena, G., Banks, V., Czira, A., Wood, R., Tritton, T., Wild, R., et al. (2022). Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β(2)-Agonist Dual Therapy in a Primary Care Setting in England. Int J Chron Obstruct Pulmon Dis, 17, 1781-1795. http://doi.org/10.2147/copd.s365480
View
Brookes, M. J., Waller, J., Cappelleri, J. C., Modesto, I., DiBonaventura, M. D., Bohm, N., et al. (2020). Living with Ulcerative Colitis Study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitis. BMJ Open Gastroenterol. http://doi.org/10.1136/bmjgast-2020-000456
View
Webb, J., Mount, J., von Arx, L. B., Rachman, J., Spanopoulos, D., Wood, R., et al. (2021). Cardiovascular risk profiles: A cross-sectional study evaluating the generalisability of the glucagon-like peptide-1 receptor agonist cardiovascular outcome trials Rewind, Leader and Sustain-6 to the real-world type 2 diabetes population in the UK. Diabetes Obes Metab. http://doi.org/10.1111/dom.14580
View